Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Aug;99(8):e147.
doi: 10.3324/haematol.2014.112482.

Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000

David S Siegel  1
Affiliations
Comment

Reply to "The challenge of cross-trial comparison using limited data" Haematologica. 2014;99(8):e000

David S Siegel. Haematologica. 2014 Aug.
No abstract available

Keywords: challenge; cross-trial; data.

PubMed Disclaimer

Comment on

References

    1. Laubach JP, Faber EA, Jr, Voorhees P, Moslehi J, Varga C, Niculescu L, et al. The challenge of cross-trial comparisons using limited data. Haematologica. 2014;99(8):xxx - PMC - PubMed
    1. Siegel D, Martin T, Nooka A, Havery RD, Vij R, Niesvizky AZ, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013;98(11):1753–61 - PMC - PubMed
    1. Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, et al. An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012; 12(5):310–8 - PubMed
    1. Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012; 120(14):2817–25 - PMC - PubMed
    1. Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012;158(6):739–48 - PMC - PubMed

MeSH terms